GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oryzon Genomics SA (XMAD:ORY) » Definitions » Debt-to-Equity

Oryzon Genomics (XMAD:ORY) Debt-to-Equity : 0.00 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Oryzon Genomics Debt-to-Equity?

Oryzon Genomics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. Oryzon Genomics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €0.00 Mil. Oryzon Genomics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was €82.35 Mil. Oryzon Genomics's debt to equity for the quarter that ended in Mar. 2024 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Oryzon Genomics's Debt-to-Equity or its related term are showing as below:

XMAD:ORY' s Debt-to-Equity Range Over the Past 10 Years
Min: 0   Med: 0.24   Max: 0.87
Current: 0.17

During the past 10 years, the highest Debt-to-Equity Ratio of Oryzon Genomics was 0.87. The lowest was 0.00. And the median was 0.24.

XMAD:ORY's Debt-to-Equity is ranked worse than
51.93% of 1063 companies
in the Biotechnology industry
Industry Median: 0.15 vs XMAD:ORY: 0.17

Oryzon Genomics Debt-to-Equity Historical Data

The historical data trend for Oryzon Genomics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oryzon Genomics Debt-to-Equity Chart

Oryzon Genomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 0.12 0.19 0.24 0.17

Oryzon Genomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.19 0.15 0.17 -

Competitive Comparison of Oryzon Genomics's Debt-to-Equity

For the Biotechnology subindustry, Oryzon Genomics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oryzon Genomics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oryzon Genomics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Oryzon Genomics's Debt-to-Equity falls into.



Oryzon Genomics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Oryzon Genomics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Oryzon Genomics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oryzon Genomics  (XMAD:ORY) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Oryzon Genomics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Oryzon Genomics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Oryzon Genomics (XMAD:ORY) Business Description

Traded in Other Exchanges
Address
Sant Ferran 74, Cornellà de Llobregat, Barcelona, ESP, 08940
Oryzon Genomics SA is a clinical stage biopharmaceutical company and engaged in the development of epigenetics-based therapeutics. It is engaged in the field of epigenetic medicine and in the development of therapeutic, biological solutions for cancer and neurodegenerative diseases.

Oryzon Genomics (XMAD:ORY) Headlines

No Headlines